Aortic Flow Propagation Velocity in Patients with Familial Mediterranean Fever: an Observational Study

Kayihan Karaman, MD1, Arif Arisoy, MD1, Aysegul Altinkas, MD2, Ertugrul Erken, MD3, Ahmet Demirtas, MD3, Mustafa Ozturk, MD3, Metin Karayakali, MD1, Safak Sahin, MD3, and Atac Celik, MD1

1Department of Cardiology, Gaziosmanpasa University School of Medicine, Tokat, 2Department of Radiology, Gaziosmanpasa University School of Medicine, Tokat, 3Department of Internal Medicine, Gaziosmanpasa University School of Medicine, Tokat, 4Department of Cardiology, Erzurum Territorial Training and Research Hospital, Erzurum, Turkey

Background and Objectives: Systemic inflammation has an important role in the initiation of atherosclerosis, which is associated with arterial stiffness (AS). Aortic flow propagation velocity (APV) is a new echocardiographic parameter of aortic stiffness. The relationship between systemic inflammation and AS has not yet been described in patients with familial Mediterranean fever (FMF). We aimed to investigate the early markers of AS in patients with FMF by measuring APV and carotid intima-media thickness (CIMT).

Subjects and Methods: Sixty-one FMF patients (43 women; mean age 27.3±6.7 years) in an attack-free period and 57 healthy individuals (36 women; mean age 28.8±7.1 years) were included in this study. The individuals with atherosclerotic risk factors were excluded from the study. The flow propagation velocity of the descending aorta and CIMT were measured to assess AS.

Results: APV was significantly lower (60.2±16.5 vs. 89.5±11.6 cm/sec, p<0.001) and CIMT was significantly higher (0.49±0.09 vs. 0.40±0.10 mm, p<0.001) in the FMF group compared to the control group. There were significant correlations between APV and mean CIMT (r=-0.424, p<0.001), erythrocyte sedimentation rate (ESR) (r=0.198, p=0.032), and left ventricle ejection fraction (r=0.201, p=0.029). APV and the ESR were independent predictors of FMF in logistic regression analysis (OR=-0.900, 95% CI=0.865-0.936, p<0.001 and OR=-1.078, 95% CI=-1.024-1.135, p=0.004, respectively). Mean CIMT and LVEF were independent factors associated with APV in linear regression analysis (β=-0.423, p<0.001 and β=0.199, p=0.017, respectively)

Conclusion: We demonstrated that APV was lower in FMF patients and is related to CIMT. According to our results, APV may be an independent predictor of FMF. (Korean Circ J 2017;47(4):483-489)

KEY WORDS: Familial Mediterranean fever; Aortic flow propagation velocity; Arterial stiffness; Carotid intima-media thickness.

Introduction

Familial Mediterranean fever (FMF) is an autosomal recessive auto-inflammatory disorder characterized by recurrent, episodic fever and acute episodes of serosal membrane inflammation (sterile pleuritis, peritonitis, arthritis, etc.). The clinical disease most commonly occurs in Jews, Turks, Armenians, and Arabs.9 The incidence of FMF is reportedly between 5/1000 in Jews and 1/1000 in Turks.21 The gene causing FMF, also designated as the Mediterranean fever (MEFV) gene, is located on the short arm of chromosome 16. This gene encodes a protein called pyrin that plays an important role in the inhibition of pro-inflammatory
cytokines, and increases the discharge of anti-inflammatory mediators by inflammatory cells such as neutrophils, eosinophils, and monocytes. Mutations in MEFV are responsible for regional and systemic inflammation.

Cardiovascular disease (CVD) is a common cause of death in patients with auto-inflammatory disorders. Recent data have demonstrated that atherosclerosis and arterial stiffness (AS) play a major role in the pathogenesis of CVD. AS, which reflects arterial compliance, is progressively being accepted as an independent predictor of cardiovascular death. Chronic systemic inflammation in FMF may increase AS by accelerating the natural process of atherosclerosis. Aortic flow propagation velocity (APV), which has been used as a new echocardiographic index of AS, is a noninvasive technique for measuring the distensibility of the aorta. Several studies have investigated the relationship between APV and endothelial dysfunction, and carotid intima-media thickness (CIMT) has been found to be associated with APV.

In this study, we aimed to investigate the early markers of AS in patients with FMF by measuring APV and CIMT.

Subjects and Methods

Patient population
This cross-sectional and case-control study included 61 patients without cardiovascular involvement in an attack-free period (18 men, 43 women; mean age, 27.3 ± 6.7 years) diagnosed with FMF in our center between August 2014 and August 2015. The diagnosis of FMF was made according to the Tel-Hashomer criteria. Fifty-seven age- and sex-matched control healthy subjects (21 men, 36 women; mean age, 28.8 ± 7.1 years) were included from our cardiology outpatient clinics. All of the patients with FMF were under regular colchicine treatment. We excluded patient and control subjects with a history of coronary artery disease, arterial hypertension, diabetes mellitus, smoking, hypercholesterolemia, left ventricle (LV) ejection fraction (LVEF) < 50%, hypertrophic or dilated cardiomyopathies, valvular heart disease, prosthetic heart valve, bundle branch block, atrial fibrillation and other electrocardiographic abnormalities, renal failure, chronic obstructive lung disease, thyroid dysfunction, other known inflammatory disease, malignancy, amyloidosis, or echocardiographic imaging that was technically insufficient. Hemoglobin, white blood cell (WBC) count, neutrophil count, lymphocyte count, neutrophil-lymphocyte ratio (NLR), erythrocyte sedimentation rate (ESR; reference range: 0-20 mm/hr), and C-reactive protein (CRP; reference range: 0-5 mg/L) levels were obtained from the laboratory records. Ethics committee approval and informed consent were obtained for all patients.

Echocardiographic evaluation
Conventional echocardiographic parameters of the patient and control subjects were performed in the left lateral decubitus position. Standard two-dimensional images were acquired by two experienced echocardiographers who were blinded to the clinical data, using a 2.5-3.5-MHz transducer (General Electric Vivid S5, Milwaukee, WI, USA). LV diameter and thickness were measured from M-mode traces from the parasternal long axis view. LVEF was assessed using the biplane-modified Simpson method. LV end-systolic and end-diastolic volumes (LVESV and LVEDV) were calculated using the biplane-modified Simpson’s rule in the apical 4- and 2-chamber views. For pulse wave Doppler measurements, the sample volume was placed in the middle of the LV inflow tract 1 cm below the plane of mitral annulus in the apical four-chamber view. Mitral early diastolic velocity (E), late diastolic velocity (A), and E/A ratio were determined.

Color M-mode Doppler measurements were obtained on the suprasternal view and recordings were obtained with the cursor parallel to the main flow of direction in the descending thoracic aorta. The color Doppler Nyquist limit is adapted to 30-50 cm/s, and switching to M mode with a recorder sweep rate of 200 mm/s, an M-mode spatio-temporal velocity map with the shape of a flame is displayed (Fig. 1). If the slope of the flame was unclear, the baseline shifting was used to change the aliasing velocity until a clear delineation of isovelocity slope was obtained. APV was then calculated by dividing the distance between the points corresponding to the beginning and end of the propagation slope by the duration between the corresponding time points. Thus, APV corresponds to the velocity at which the flow is propagating down the artery. The mean of at least three measurements was recorded as the APV value.

Carotid intima-media thickness measurement
Carotid intima-media thickness (CIMT) measurements of the participants were performed by physicians who were blinded to the patients and obtained APV values. Both common carotid arteries were analyzed with a Toshiba Apio 500 (Toshiba Medical System, Tokyo, Japan) ultrasound device with a 7.5 MHz linear probe, and the CIMT was automatically measured with software. CIMT was measured at the posterior wall when they were clearly visible in the longitudinal plane at 1-1.5 cm below bifurcation. The CIMT measurement was obtained from three contiguous sites at 1-mm intervals. The average of the three measurements and the mean of the left and right common carotid arteries were used for analyses.

Pearson correlation analysis was performed to assess intra- and interobserver variability. Intraobserver variability for APV and CIMT were 3.1% and 1.8%, respectively (p > 0.05). In addition, the interobserver variability for APV and CIMT were 3.4% and 2.0%, respectively (p > 0.05).
Statistical analysis

All tests were performed using PASW Statistics v18.0. Variables with a normal distribution were analyzed using the Kolmogorov–Smirnov test. Continuous variables are expressed as mean±standard deviation, while categorical variables are presented as numbers and percentages. Differences between independent groups were assessed by Student’s t-test for normally distributed continuous variables and Mann-Whitney’s U-test for variables without normal distribution. Categorical variables were assessed by the chi-square test. Correlations between parameters with normal and non-normal distribution were computed through Pearson’s and Spearman’s correlation analysis, respectively. Logistic regression analysis was used to analyze independent predictors of FMF, and linear regression analysis was used to analyze independent predictors of APV. The sensitivity and specificity of APV to predict FMF was evaluated with receiver operative characteristic (ROC) analysis. The area under curve (AUC) was obtained. All results were considered statistically significant at the level of p<0.05.

Results

Clinical characteristics and laboratory findings from patients with FMF and control subjects are shown in Table 1. The distributions of age, sex, body mass index (BMI), systolic and diastolic blood pressure, lipid profile, CRP, WBC count and NLR were similar between the two groups. However, ESR was significantly higher in the FMF patients compared with the control group. The two-dimensional echocardiography and the Doppler study variables are shown in Table 2. LV diameters, LV volumes, LVEF, interventricular septum (IVS) thickness, mitral E and A velocity ratio were similar in both groups. However, the mean CIMT was significantly higher, and APV was significantly lower in FMF patients. Mean disease and treatment durations in patients with FMF were 95.9±59.9 and 52.9±52.7 months, respectively.

There were significant correlations between APV and mean CIMT (r=-0.424, p<0.001) (Fig. 2), ESR (r=-0.198, p=0.032), and LVEF (r=0.201, p=0.029). However, there was no correlation among APV, age, CRP, NLR, and WBC count (Table 3). Moreover, mean CIMT was significantly correlated with age (r=0.360, p<0.001), BMI (r=0.208, p=0.024), total cholesterol (r=0.207, p=0.024), LDL cholesterol (r=0.252, p=0.006), and ESR (r=0.351, p<0.001).

APV (OR=-0.900, 95% CI=0.865-0.936, p<0.001) and the ESR (OR=-1.078, 95% CI=1.024-1.135, p=0.004) were independent predictors associated with FMF in logistic regression analysis (Table 1, 2). Receiver–operating characteristic (ROC) curve analysis suggested that the optimum APV cutoff point for patients with FMF was 69.6 cm/s, predicted FMF with 77.1% sensitivity and 96.5% specificity. The area under curve was 0.912 (95% CI = 0.846-0.956, p<0.001) (Fig. 3). Mean CIMT and LVEF were the independent factors associated with APV (β=-0.423, p<0.001 and β=0.199, p=0.017, respectively) (Table 3). On the other hand, APV and mean CIMT (r=0.245, p=0.057 and r=0.074, p=0.573, respectively) values showed no significant correlation with mean disease and treatment durations in patients with FMF.

Discussion

In this study, the presence of subclinical atherosclerosis was first demonstrated in patients with FMF using the APV method. The flow propagation velocity parameter in the arterial lumen derived from the APV method was decreased in FMF patients with no clinical symptoms of heart disease compared to the control group. Moreover, we showed that APV was correlated with mean CIMT, ESR, and LVEF and it was an independent predictor associated with FMF.
FMF is characterized by localized and systemic inflammation that affects serous cavities such as the peritoneum, pleura, pericardium, and joints. In addition, an increased risk of ventricular arrhythmia, conduction defects, and cardiac autonomic dysfunction has been described in these patients. Subclinical inflammation continues during the attack-free period in patients with FMF. However, the levels of some inflammatory markers, such as CRP and fibrinogen, are lower during attack-free periods. The levels of these markers increase during attack periods; however, they are usually normal in between attacks. Impaired cardiovascular function in FMF patients may be associated with continuing subclinical inflammation.

Therefore, because it is related to atherosclerosis, early diagnosis of subclinical inflammation has become increasingly important. Subclinical inflammation plays a major role in the pathogenesis of atherosclerosis in different auto-inflammatory diseases, and increases the incidence of cardiovascular events and mortality.

Table 1. Demographic and biochemical characteristics in patients with FMF and controls

|                          | FMF Patients (n=61) | Control group (n=57) | p*   | OR (95% CI) | p**  |
|--------------------------|---------------------|----------------------|------|-------------|------|
| Age (year)               | 27.3±6.7            | 28.8±7.1             | 0.251|             |      |
| Female                   | 43 (70.5)           | 36 (63.2)            | 0.397|             |      |
| BMI (kg/m²)              | 23.6±4.7            | 23.9±3.3             | 0.667|             |      |
| Systolic BP (mmHg)       | 109.6±11.2          | 111.5±9.4            | 0.330|             |      |
| Diastolic BP (mmHg)      | 70 (70-80)          | 70 (65-80)           | 0.839|             |      |
| Heart rate (beats/min)   | 77.4±12.8           | 79.6±12.4            | 0.339|             |      |
| Total cholesterol (mg/dL)| 158 (145-178)       | 164 (142-180)        | 0.499|             |      |
| Triglyceride (mg/dL)     | 89 (73-110)         | 105 (62-134)         | 0.279|             |      |
| HDL-C (mg/dL)            | 43.3±16.4           | 46.4±12.6            | 0.248|             |      |
| LDL-C (mg/dL)            | 101.9±26.6          | 102.8±35.6           | 0.877|             |      |
| CRP (mg/dL)              | 3.75 (3.40-9.65)    | 3.45 (3.30-4.43)     | 0.110|             |      |
| ESR (mm/h)               | 9 (4-21)            | 5 (2-8)              | <0.001| 1.078 (1.024-1.135) | 0.004|
| NLR                      | 1.78 (1.41-2.53)    | 1.82 (1.39-2.05)     | 0.190|             |      |
| WBC count (×10^9/L)      | 7.21±1.92           | 7.54±1.82            | 0.346|             |      |

Values are presented as mean±standard deviation or number (%). *Independent samples t-test or Mann-Whitney U test, **logistic regression analysis. FMF: familial Mediterranean fever, OR: odds ratio, CI: confidence interval, BP: blood pressure, BMI: body mass index, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, NLR: neutrophil-lymphocyte ratio, WBC: white blood cell

Table 2. Echocardiographic findings in patients with familial Mediterranean fever and controls

|                          | FMF patients (n=61) | Control group (n=57) | p*   | OR (95% CI) | p**  |
|--------------------------|---------------------|----------------------|------|-------------|------|
| LVEDD (mm)               | 45.1±2.9            | 45.2±3.6             | 0.830|             |      |
| LVESD (mm)               | 30 (29-32)          | 29 (27-32)           | 0.166|             |      |
| LVEDV (mL)               | 85.4±16.3           | 88.8±13.8            | 0.232|             |      |
| LVESV (mL)               | 35.7±9.0            | 35.5±7.5             | 0.918|             |      |
| LVEF                     | 58.5±5.1            | 60.3±4.9             | 0.053|             |      |
| IVS (mm)                 | 8 (8-9)             | 9 (8-10)             | 0.111|             |      |
| E/A                      | 1.64±0.5            | 1.53±0.44            | 0.237|             |      |
| Mean CIMT (mm)           | 0.49±0.09           | 0.40±0.10            | <0.001| 15.11 (0.035-6471.62) | 0.38|
| APV (cm/sec)             | 60.2±16.5           | 89.5±11.6            | <0.001| 0.900 (0.865-0.936) | <0.001|

Values are presented as mean±standard deviation or number (%). *Independent samples t-test or Mann-Whitney U test, **logistic regression analysis. LVEDD: left ventricular end-diastolic diameter, LVESD: left ventricular end-systolic diameter, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume, LVEF: left ventricular ejection fraction, IVS: interventricular septum thickness, E/A: mitral E and A velocity ratio, CIMT: carotid intima-media thickness, APV: aortic propagation velocity
inflammatory diseases. For example, Demiralp et al. investigated changes in aortic elasticity in ankylosing spondylitis patients. They reported that aortic elasticity decreased independently of disease duration, and that the mean aortic stiffness index was increased, as compared to the control group. Similar to the above study, Bicer et al. found that the aortic stiffness index in psoriasis vulgaris patients was higher than in the control group. These modifications in the arterial wall are mediated by the development of atherosclerosis and can be explained by inflammation. However, the exact mechanism underlying the association between FMF and the cardiovascular involvement is not fully understood.

Prior studies have shown that increased AS is an important marker of increased cardiovascular mortality and morbidity. Therefore, several noninvasive methods, such as CIMT, ankle brachial index, and carotid-femoral pulse wave velocity (PWV), were developed to detect AS in daily practice. Color M-mode propagation velocity provides the spatiotemporal map of blood flow velocities along the arterial lumen. Increased AS may decrease the flow propagation velocity with increased downstream resistance within the arterial lumen. Based on this, we investigated the association between APV with CIMT and inflammatory markers in patients with FMF.

Previous studies have shown a strong association between

| Table 3. Relationship between APV and clinical and echocardiographic variables |
|---------------------------------------------------------------|
| **Pearson correlation coefficient** | **p** | **Spearman correlation coefficient** | **p** | **Beta regression coefficient** | **p** |
| Mean CIMT | -0.424 | <0.001 | -0.423 | <0.001 |
| LVEF | 0.201 | 0.029 | 0.199 | 0.017 |
| Age | -0.018 | 0.849 |
| BMI | -0.035 | 0.708 |
| IVS | -0.030 | 0.743 |
| E/A | 0.023 | 0.803 |
| WBC | -0.023 | 0.803 |
| CRP | -0.059 | 0.529 |
| ESR | -0.198 | 0.032 | 0.154 | 0.187 |
| NLR | 0.004 | 0.968 |

Pearson and spearman correlation analyses, and linear regression analysis. APV: aortic propagation velocity, CIMT: carotid intima-media thickness, LVEF: left ventricular ejection fraction, BMI: body mass index, IVS: interventricular septum thickness, E/A: mitral E and A velocity ratio, WBC: white blood cell, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, NLR: neutrophil-lymphocyte ratio.
coronary artery disease and atheroma plaques in thoracic aorta imaged by transesophageal echocardiography (TEE). However, the use of TEE for assessment of cardiovascular involvement is not feasible in daily practice. While APV, which could be used in echocardiographic examinations, is accepted as a simple, noninvasive, reproducible technique for determining general atherosclerosis severity, it may also be used to determine AS. Several previous studies have investigated the use of APV to determine the association between AS of many diseases such as hypertension, coronary artery disease, and type-2 diabetes mellitus, and demonstrated that APV was significantly lower in these diseases. However, our knowledge on the effects of subclinical inflammation on APV in patients with inflammatory disease is limited.

Carotid-femoral PWV has been identified as the gold standard for evaluating AS. A large number of inflammatory markers were found to be associated with AS, which was determined using carotid-femoral PWV in various studies. For example, in a study by Yi et al., CRP and carotid-femoral PWV levels were increased in psoriatic patients compared to healthy individuals, and a correlation was observed between CRP and carotid-femoral PWV. In another study, the investigators showed that carotid-femoral PWV was correlated with CRP in rheumatoid arthritis patients. In one study, Yildirim et al. demonstrated a correlation between carotid-femoral PWV and WBC count in patients with FMF, but no correlation between carotid-femoral PWV and CRP. In our study, ESR was significantly higher in FMF patients, and APV was correlated with ESR levels. In addition, ESR was a significant predictor of FMF. The lack of correlation between APV and inflammatory markers, such as CRP, WBC count, and NLR, may be explained by the fact that these markers were measured during the attack-free period. Interestingly, some studies have shown that subclinical inflammation is maintained in up to one-third of FMF patients during attack-free periods. Yildirim et al. demonstrated that IL-1β levels are increased during attack-free periods in FMF patients, and these values appear to correlate with CRP levels. APV and immunological cytokines could not be compared between the FMF patients and control subjects, and this was a major deficiency in the power of our study. On the other hand, lack of correlation between mean disease and treatment durations with APV and mean CIMT shows that these values might be associated with the frequency and severity of attacks rather than disease duration alone.

Assessment of CIMT has been commonly used as a simple and noninvasive marker for early and preclinical atherosclerosis. An increase in CIMT is an important risk factor for systemic atherosclerosis. Recent studies have demonstrated significantly increased CIMT values in FMF patients compared to healthy controls. Similar to previous studies, we found that the mean CIMT was significantly increased in patients with FMF. At the same time, we found a negative correlation between the APV and mean CIMT values.

Study limitations
Our study had some limitations. The most important limitation is that the echocardiographic image quality may cause difficulties in the measurement of APV. The second limitation was the restricted number of patients included in the study, which may have negatively affected the statistical power of the study. Third, long-term effects of subclinical inflammation on AS in patients with FMF could not be determined because of the cross-sectional nature of our study design. Fourth, the APV assessment using the color M-mode method of the aortic flow propagation velocity had some potential errors. The points corresponding to the beginning and end of the propagation slope should be performed very carefully; small placement errors may lead to significant mistakes in the calculation. Finally, our study was performed at a single center. Therefore, our findings must be confirmed via prospective, multicenter studies with long-term follow-up.

Conclusions
We have shown for the first time that patients with FMF have a lower APV value than control subjects. We also found a positive correlation between APV and mean CIMT, and APV was an independent predictor of FMF. A decreased APV value may be related to endothelial dysfunction and may reflect the effect of subclinical inflammation in patients with FMF without cardiovascular involvement. Furthermore, comprehensive studies are needed to explore the potential relationship between AS and this new index.

References
1. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998;351:659-64.
2. Stoffman N, Magal N, Shohat T, et al. Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet 2000;8:307–10.
3. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 2001;9:473-83.
4. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004;63:952-5.
5. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
6. Simsek H, Sahin M, Gunes Y, Dogan A, Gumrukcuoglu HA, Tuncer M.

https://doi.org/10.4070/kcj.2016.0400 www.e-kcj.org
A novel echocardiographic method for the detection of subclinical atherosclerosis in newly diagnosed, untreated type 2 diabetes. *Echocardiography* 2013;30:644-8.

7. Sen T, Tufekcioglu O, Ozdemir M, et al. New echocardiographic parameter of aortic stiffness and atherosclerosis in patients with coronary artery disease: aortic propagation velocity. *J Cardiol* 2013;62:236-40.

8. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. *Mod Rheumatol* 2009;19:550-5.

9. Akcay A, Acar G, Sayarioglu M, et al. QT dispersion and transmural dispersion of repolarization in patients with familial Mediterranean fever. *Med Sci Monit* 2008;14:MT42-6.

10. Levy M, Ehrenfeld M, Levo Y, Fischel R, Zlotnick A, Eliakim M. Circulating immune complex in recurrent polyserositis. (Familial mediterranean fever periodic disease). *J Rheumatol* 1980;7:886-90.

11. Berkun Y, Padeh S, Reichman B, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. *Semin Arthritis Rheum* 2007;37:182-8.

12. Yildirim K, Uzkeser H, Keles M, et al. Relationship between serum interleukin-1beta levels and acute phase response proteins in patients with familial Mediterranean fever. *Biochemia Med (Zagreb)* 2012;22:109-13.

13. Ossareh S, Alaei A, Saedi D. Carotid intima-media thickness in maintenance hemodialysis patients: role of cardiovascular risk factor. *Iran J Kidney Dis* 2011;5:169-74.

14. Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima-media thickening in patients with familial Mediterranean fever. *Rheumatology (Oxford)* 2009;48:911-5.